Along with other novel approaches [41–43], the pharmacologic targeting of MIF either by monoclonal antibodies or by small molecule antagonists for the treatment of autoimmune diseases has attracted considerable interest and new generation inhibitors are actively investigated [44,45]. Here, MIF is linked to autoimmune disease.